Bausch + Lomb trumps failed Valeant bid for ISTA with $500m deal
This article was originally published in Scrip
Executive Summary
Eye care firm Bausch + Lomb has agreed to acquire ISTA Pharmaceuticals for $9.10 per share, or around $500 million in total, in cash. The deal represents a premium of 10% to ISTA's share price on 23 March, the last trading day before the transaction went public yesterday, and trumps the salvo of hostile offers from Valeant Pharmaceuticals, which rapidly escalated its bid from $6.50 per share last December through $7.50 to $8.50, but then withdrew from the running as its debt was downgraded by Moody's (scripintelligence.com, 31 January 2012).
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.